IP Library Granted Patent US 7,378,469
Granted Patent B2
US 7,378,469 · App. 11/492,133 · Granted May 27, 2008

Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,469
App. No.
11/492,133
Granted
May 27, 2008
Kind
B2
Abstract

The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate ester can then be reacted directly with a biologically active agent to form a biologically active polymer conjugate or reacted with an amino acid, such as lysine, to form an amino acid derivative.

Claims (29)

1. A method for making a polymer conjugate, said method comprising:

(i) providing a water-soluble and non-peptidic polymer having at least one terminal hydroxyl group;

(ii) reacting the terminal hydroxyl group of the water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate (di-BTC) to form a 1-benzotriazolylcarbonate ester of the water-soluble and non-peptidic polymer (polymer BTC ester), and

(iii) reacting the 1-benzotriazolylcarbonate ester of the water-soluble and non-peptidic polymer with a biologically active agent under conditions effective to form a polymer conjugate.

2. The method of claim 1 , wherein the biologically active agent comprises a nucleophilic functional group capable of reacting with said polymer BTC ester; and said BTC ester is reacted with said biologically active agent.

3. The method of claim 2 , wherein said nucleophilic functional group is an amine.

4. The method of claim 1 , wherein said biologically active agent is selected from the group consisting of peptides, proteins, enzymes, small molecule drugs, dyes, lipids, nucleosides, oligonucleotides, cells, viruses, liposomes, microparticles and micelles.

5. The method of claim 1 , wherein the water-soluble and non-peptidic polymer is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxypropylmethacrylamide), poly(α-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), and copolymers, terpolymers, and mixtures thereof.

6. The method of claim 5 , wherein the water-soluble and non-peptidic polymer is a poly(ethylene glycol).

7. The method of claim 6 , wherein the poly(ethylene glycol) is selected from the group consisting of alkoxy poly(ethylene glycol), difunctional poly(ethylene glycol), multi-armed poly(ethylene glycol), forked poly(ethylene glycol), branched poly(ethylene glycol), and pendent poly(ethylene glycol).

8. The method of claim 6 , wherein the poly(ethylene glycol) comprises a degradable linkage.

9. The method of claim 6 , wherein the poly(ethylene glycol) has an average molecular weight from about 200 Da to about 100,000 Da.

10. The method of claim 6 , wherein the poly(ethylene glycol) comprises the formula: —CH 2 CH 2 O—(CH 2 CH 2 O) n —CH 2 CH 2 —, where n is from about 3 to about 4000.

11. The method of claim 10 , wherein the poly(ethylene glycol) comprises the formula: —CH 2 CH 2 O—(CH 2 CH 2 O) n —CH 2 CH 2 —, where n is from about 3 to about 2000.

12. The method of claim 7 , wherein the poly(ethylene glycol) is branched.

13. The method of claim 12 , wherein the poly(ethylene glycol) has a central branch core and a plurality of linear poly(ethylene glycol) chains linked to the central branch core.

14. The method of claim 13 , wherein said central branch core is derived from a polyol selected from glycerol, pentaerythritol, and sorbitol.

15. The method of claim 1 , wherein the water-soluble and non-peptidic polymer in step (i) has the structure R′-POLY-OH and the 1-benzotriazolylcarbonate ester of the water-soluble and non-peptidic polymer has the structure:

wherein POLY is a water-soluble and non-peptidic polymer backbone and R′ is a capping group.

16. The method of claim 15 , wherein R′ is methoxy.

17. The method of claim 15 , wherein R′ is a functional group selected from the group consisting of hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, protected amine, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxal, dione, mesylate, tosylate, and tresylate.

18. The method of claim 1 , wherein said reacting step (ii) is conducted in an organic solvent.

19. The method of claim 18 , wherein the organic solvent is selected from the group consisting of methylene chloride, chloroform, acetonitrile, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, and mixtures thereof.

20. The method of claim 1 , wherein said reacting step (ii) is conducted in the presence of a base.

21. The method of claim 20 , wherein the base is selected from the group consisting of pyridine, dimethylaminopyridine, quinoline, trialkylamines, and mixtures thereof.

22. The method of claim 1 , wherein the molar ratio of di(1-benzotriazolyl) carbonate to the water-soluble and non-peptidic polymer is about 30:1 or less.

23. The method of claim 6 , wherein said biologically active agent is a peptide or protein, and said polymer conjugate comprises a carbamate linkage between said protein or peptide and said polymer.

24. The method of claim 4 , wherein said biologically active agent is a small molecule drug.

25. The method of claim 23 , wherein step (iii) results in formation of a mixture of polymer conjugates selected from the group consisting of mono-PEGylated peptide or protein, di-PEGylated peptide or protein, tri-PEGylated peptide or protein, and tetra-PEGylated peptide or protein.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
MERGER Recorded Aug 31, 2009
From: NEKTAR THERAPEUTICS AL, CORPORATION
To: NEKTAR THERAPEUTICS
Reel/Frame 023196/0394 →